Acurx Pharmaceuticals Announces Intent For Further Discussion With FDA Regarding Ibezapolstat's Phase 3 Clinical Program, Scope Of Its Planned NDA
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced the successful outcome of a Type C
Acurx is talking more with the FDA about their new antibiotic medicine and how to test it before selling it. This is a normal step that shows the company and FDA are working together, so watch to see what the FDA says next.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.